High-dose-rate brachytherapy of primary cutaneous B-cell lymphoma: the first reported case series.
B-cell lymphomas
HDR
brachytherapy
skin
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
17
04
2020
accepted:
19
05
2020
entrez:
23
7
2020
pubmed:
23
7
2020
medline:
23
7
2020
Statut:
ppublish
Résumé
Cutaneous B-cell lymphomas (CBCLs) are a rare group of diseases. External beam radiation therapy is recommended to treat CBCLs in all subtypes for locally advanced cases. However, there are no reports on high-dose-rate brachytherapy (HDR-BT) exclusively dedicated to CBCLs. The purpose of this paper was to report the first case series of CBCLs treated with HDR-BT. Seven patients were treated between 2011 and 2019, with 12 skin lesions histopathologically proven as CBCLs. There were four T1a and eight T2a lesions. HDR-BT was prescribed as the first-line treatment for all cases, as the second-line treatment for recurrences after surgical failure for 4 patients, and as an adjuvant treatment for 1 case. The median total dose was 36 Gy (range, 30-40 Gy) in 10 fractions (range, 6-10 fractions), with a median overall treatment time of 11 days (range, 4-11 days). Treatment toxicity was assessed accordingly to the RTOG scale. The mean follow-up was 41 months. Local control was 100%. The rates of early toxicity were as follows: erythema (G1) - 33%, patchy epidermal desquamation (G2) - 25%, confluent epidermal desquamation (G3) - 25%, and minor bleeding (G4) - 17%. The reported rates of late toxicity included slight depigmentation (G1) - 59%, small telangiectasia (G2) - 8%, massive telangiectasia (G3) - 25%, and small ulceration (G4) in one site irradiated interstitially (8%). HDR-BT allows for achieving high local control of CBCLs with relatively low-late toxicity in the form of skin discoloration in most patients.
Identifiants
pubmed: 32695195
doi: 10.5114/jcb.2020.96864
pii: 41151
pmc: PMC7366024
doi:
Types de publication
Journal Article
Langues
eng
Pagination
241-247Informations de copyright
Copyright © 2020 Termedia.
Déclaration de conflit d'intérêts
The authors report no conflict of interest.
Références
Radiology. 2012 Sep;264(3):627-31
pubmed: 22919036
Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):17-22
pubmed: 11163493
Blood. 2005 May 15;105(10):3768-85
pubmed: 15692063
J Am Acad Dermatol. 2013 Jul;69(1):61-5
pubmed: 23453243
Blood. 2008 Sep 1;112(5):1600-9
pubmed: 18567836
J Contemp Brachytherapy. 2016 Dec;8(6):533-540
pubmed: 28115960
Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):899-906
pubmed: 12605967
Eur J Cancer. 1992;28A(11):1783-91
pubmed: 1389511
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792
J Contemp Brachytherapy. 2017 Dec;9(6):581-589
pubmed: 29441104
J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51
pubmed: 10922409
Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):32-9
pubmed: 25863751
Blood. 2019 Apr 18;133(16):1703-1714
pubmed: 30635287
Radiother Oncol. 2018 Mar;126(3):377-385
pubmed: 29455924
JAMA Dermatol. 2015 Dec 1;151(12):1354-1357
pubmed: 26397774
Blood. 2007 Jul 15;110(2):479-84
pubmed: 17339420